Modality
siRNA
MOA
PARPi
Target
TYK2
Pathway
Cell Cycle
Ewing Sarcoma
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
Sep 2017
→ Jun 2025
Phase 1Current
NCT03668579
11 pts·Ewing Sarcoma
2023-12→2025-06·Terminated
NCT04427674
1,305 pts·Ewing Sarcoma
2017-09→TBD·Active
1,316 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-0810mo agoInterim· Ewing Sarcoma
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P1
Active
P1
Termina…
Catalysts
Interim
2025-06-08 · 10mo ago
Ewing Sarcoma
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03668579 | Phase 1 | Ewing Sarcoma | Terminated | 11 | VA |
| NCT04427674 | Phase 1 | Ewing Sarcoma | Active | 1305 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT | |
| COR-9566 | Corcept | Approved | TYK2 |